500 Collins Street
Level 15
Melbourne, VIC 3000
Australia
61 3 9629 5566
https://www.paradigmbiopharma.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC | Founder, MD & Executive Chairman | 1,75M | N/A | 1959 |
Dr. Donna L. Skerrett M.D., MS | Chief Medical Officer and Executive Director | 1,26M | N/A | 1957 |
Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | Interim Company Secretary & Interim CFO | N/A | N/A | N/A |
Dr. Ravi Krishnan | Chief Scientific Officer | N/A | N/A | N/A |
Mr. Simon White | Director of Investor Relations | N/A | N/A | N/A |
Dr. Michael Imperiale | Global Head of Drug Safety & MPS | N/A | N/A | N/A |
Ms. Beverley Huttmann | Commercial Head | N/A | N/A | N/A |
Ms. Michelle Coffey | Global Head of Regulatory Affairs | N/A | N/A | N/A |
Dr. Mukesh Ahuja | Global Clinical Head of OA | N/A | N/A | N/A |
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Paradigm Biopharmaceuticals Limiteds ISS Governance QualityScore, Stand 1. April 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 10, Shareholderrechte: 1, Kompensation: 8.